A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
Trial details
- Registry ID
- NCT03762850
- Phase
- Phase 3
The FDA approved sparsentan (RE-021) on 17 Feb 2023.
Drug identity checked against registry records
Also recorded as RE-021
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyNCT03762850 | TVTX | Phase 3 | Completed | 2023-08-07Actual |
| Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)NCT03493685 | TVTX | Phase 3 | Completed | 2023-03-20Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2023-02-17Day | sparsentan | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA216403", "applicant_as_listed_by_fda": "TRAVERE", "brand_names": ["FILSPARI"], "active_ingredients": ["SPARSENTAN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20230217", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |